NCT06068829: Inebilizumab and Rituximab in Neuromyelitis Optica Spectrum Disorders |
|
|
| Not yet recruiting | N/A | 80 | NA | Inebilizumab, Rituximab(RTX) | Feng Jinzhou | Neuromyelitis Optica Spectrum Disorders | 06/24 | 06/25 | | |
NCT06118398: Efgartigimod in Acute Neuromyelitis Optica Spectrum Disorders |
|
|
| Not yet recruiting | N/A | 24 | NA | Intravenous methylprednisolone (IVMP) and Efgartigimod, IVMP | Feng Jinzhou | Neuromyelitis Optica, Efgartigimod | 11/24 | 05/25 | | |
NCT05891379: Inebilizumab in Acute Neuromyelitis Optica Spectrum Disorders |
|
|
| Not yet recruiting | N/A | 50 | NA | Inebilizumab, oral immunosuppressant | Xuanwu Hospital, Beijing, Jiangsu Hansoh Pharmaceutical Co., Ltd. | Neuromyelitis Optica Spectrum Disorder | 07/25 | 07/25 | | |
